Oxford Biomedica plc reiterated earnings guidance for the year 2024. For the year, the company expected total Group revenues of between £126 million and £134 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
331.5 GBX | +1.69% | +4.41% | +50.68% |
05-09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
05-09 | Molten Ventures wins UK MoD supply contract | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.68% | 414M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024